SC
DNTH icon

Stempoint Capital’s Dianthus Therapeutics DNTH Stock Holding History

Stempoint Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18M Buy
85,502
+6,218
+8% +$360K 1.37% 27
2025
Q4 		$3.27M Buy
79,284
+37,902
+92% +$1.47M 0.56% 48
2025
Q3 		$1.63M Buy
+41,382
New +$1.06M 0.33% 54
2024
Q2 		– Sell
-43,456
Closed -$1.3M – 56
2024
Q1 		$1.3M Buy
+43,456
New +$945K 0.34% 42

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stempoint Capital's DNTH Position: Q1 2026 in Review

Stempoint Capital increased its Dianthus Therapeutics (DNTH) stake by 7.8% in Q1 2026, buying an estimated $360K and bringing the position to 85,502 shares worth $7.18M. The position accounts for 1.37% of the portfolio, ranked #27.

Stempoint Capital first reported a position in DNTH in Q1 2024 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Stempoint Capital held 85,502 shares of Dianthus Therapeutics worth $7.18M as of Q1 2026.
  • Stempoint Capital bought 6,218 Dianthus Therapeutics shares in Q1 2026, an estimated $360K.
  • Dianthus Therapeutics made up 1.37% of Stempoint Capital's portfolio in Q1 2026, its #27 holding.
  • Stempoint Capital first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.